Search Browse Earnings

Climb Bio, Inc.

Nasdaq:CLYM

Pharmaceutical Preparations·WELLESLEY HILLS, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Climb Bio, Inc. — SlamSEC

Revenue

—

Adj. EBITDA

-$82.0M

FY 2025

Net Income

-$73.9M

FY 2025

EPS (Diluted)

-$1.53

FY 2025

Stock Price

$7.38

-0.1%

2026-03-09

52W Range

$1.05 – $7.59

P/E Ratio

-4.8x

Market Cap

$352.5M

Cash

$87.2M

FY 2025

Total Debt

—

Net Cash

$87.2M

Enterprise Value

$265.3M

Debt / EBITDA

1.1x

FY 2025

EV / EBITDA

-3.2x

Employees

—